Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Large Cap | Pharmaceuticals & Drugs
1175.55
-10.90 (-0.92%)
< Home < Back

Dr. Reddy's Laboratories launches Treprostinil Injection in U.S. market

Date: 21-04-2023

Dr. Reddy's Laboratories has launched Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA). The company’s Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.